Celleration, Inc., an early stage operating company, the developer of a non-contact
ultrasound therapy treatment for chronic and hard to heal wounds, announced
today it has closed $20.6 million in Series C financing. Jeffries Broadview
advised the Company and served as the placement agent for this transaction.
New investors include Triathlon Medical Ventures and New Science Ventures, which
co-led the round, with Baird Venture Partners, CID Capital and Seneca Health
Partners following. Follow-on investors included Affinity Ventures, Upper Lake
Growth Capital, Prism, Venture Investors and AAVIN Equity Partners.
American Venture Magazine